Mallinckrodt Pharmaceuticals Sustainability Profile
Mallinckrodt Pharmaceuticals, a global leader in specialty pharmaceuticals, is headquartered in the United Kingdom. Founded in 1867, the company has established a strong presence in key operational regions, including North America and Europe. With a focus on pain management, autoimmune disorders, and critical care, Mallinckrodt is renowned for its innovative therapies and unique formulations. The company’s core products, such as specialty generics and branded medications, are designed to address complex medical needs, setting them apart in a competitive market. Notable achievements include a robust portfolio of FDA-approved treatments and a commitment to advancing patient care through research and development. As a trusted name in the pharmaceutical industry, Mallinckrodt continues to make significant strides in improving health outcomes worldwide.
DitchCarbon Score
How does Mallinckrodt Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Mallinckrodt Pharmaceuticals's score of 38 is higher than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Mallinckrodt Pharmaceuticals's reported carbon emissions
In 2022, Mallinckrodt Pharmaceuticals reported total carbon emissions of approximately 171,898,000 kg CO2e, comprising 89,551,000 kg CO2e from Scope 1 and 82,347,000 kg CO2e from Scope 2 emissions. The company has set ambitious climate commitments, aiming to reduce its Scope 1 and Scope 2 emissions by 30% from a 2022 baseline by 2030. Additionally, Mallinckrodt is targeting near-zero emissions for both Scope 1 and Scope 2 by the middle of this decade (2023-2025). This emissions data is cascaded from Mallinckrodt Pharmaceuticals Limited, which operates as a current subsidiary under Mallinckrodt plc. The company is actively working towards these reduction targets as part of its sustainability strategy, reflecting a commitment to addressing climate change and reducing its environmental impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2022 | |
|---|---|---|---|
| Scope 1 | - | - | 00,000,000 |
| Scope 2 | - | - | 00,000,000 |
| Scope 3 | - | - | - |
How Carbon Intensive is Mallinckrodt Pharmaceuticals's Industry?
How Carbon Intensive is Mallinckrodt Pharmaceuticals's Location?
Mallinckrodt Pharmaceuticals's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Mallinckrodt Pharmaceuticals has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
